Should vascular effects of newer treatments be addressed more completely?

Future Oncology

Volumn 11, Issue 14, 2015, Pages 1995-1998

  Yang, Eric H ^a   Watson, Karol E ^a   Herrmann, Joerg ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

cardio oncology; cardiotoxicity; dasatinib; imatinib resistance; leukemia; nilotinib; peripheral arterial disease; ponatinib; tyrosine kinase inhibitors; vascular toxicity

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; BAFETINIB; BCR ABL PROTEIN; DASATINIB; HEPARIN; HISTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; XL 228; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMPUTATION; ANGIOPLASTY; ANKLE BRACHIAL INDEX; ANTIHYPERTENSIVE THERAPY; ARTERIAL THROMBOEMBOLISM; ATHEROSCLEROSIS; BYPASS SURGERY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOME 22; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CLAUDICATION; COMORBIDITY; DRUG EXPOSURE; DRUG POTENCY; DRUG SAFETY; ECHOGRAPHY; FOOD AND DRUG ADMINISTRATION; GANGRENE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; INFECTION; MYELOPROLIFERATIVE DISORDER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLEURA EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL TIME; THROMBOEMBOLISM; WILD TYPE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DASATINIB; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PYRIDAZINES;

EID: 84937794972     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.119     Document Type: Review

References (20)

1. Hermann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin. Proc. 89, 1287-306 (2014
2. Herrmann J, Lerman A. An update on cardio-oncology. Trends Cardiovasc. Med. 24, 285-295 (2014
3. Druker BJ, Guilhot F, OBrien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006
4. Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 16, 122-131 (2009
5. Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin. Lymphoma, Myeloma Leukemia 13, 515-529 (2013
6. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and philadelphia chormosome-positive ALL. N. Engl. J. Med. 354, 2542-2551 (2006
7. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukema. N. Engl. J. Med. 362, 2251-2259 (2010
8. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531-2541 (2006
9. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory philadelphia chromosome-positive leukemias. N. Engl. Med. 367, 2075-2088 (2012
10. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125, 2128-2137 (2012
11. Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am. J. Hematol. 86, 533-539 (2011
12. Valent P, Hadzijusufovic E, Schemthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 125, 901-906 (2015
13. Mirault T, Rea D, Azarine A, Messas E. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome. Eur. J. Hematol.94, 363-367 (2014).
14. Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur. J. Hematol. 90, 531-532 (2013
15. Tefferi A, Lentendre L. Nilotinib treatment-Associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am. J. Hematol. 86, 610-611 (2011
16. Quintas-Caradama A, Kantarjian H, Cortes J. Nilotinib-Associated vascular events. Clin. Lymphoma Myeloma Leuk. 12, 337-340 (2012
17. Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 27, 1316-1321 (2013
18. Cortes JE, Kim DW, Pinilla-Ibarz P, et al A Phase 2 trial of ponatinib in philadelphia chromosome-positive leukemias. N. Engl. J. Med. 369, 1783-1796 (2013
19. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-Analysis. JAMA 300, 197-208 (2008
20. Breccia M, Colafigli G, Molica M, Alimena G. Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. Am. J. Hematol. 90, E100-E101 (2015